# A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients

> **NCT04041011** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 23 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** 1.Experimental: A (Part 1): Fluzoparib and SHR -1316
- **DRUG:** 2.Experimental: B (Part 1): Fluzoparib and SHR -1316
- **DRUG:** 3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion

## Key facts

- **NCT ID:** NCT04041011
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-17
- **Primary completion:** 2021-04-23
- **Final completion:** 2021-04-23
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04041011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04041011, "A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04041011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*